LIPO
LIPELLA PHARMACEUTICALS INC.
- PER (TTM)
- -
- PER (Forward)
- -0.01
- EPS (TTM)
- -
- EPS (Forward)
- -
- PBR
- 0.09
- 시가총액
- 138,625
- 배당수익률
- -
- 베타
- 0.84
- 1개월 수익률
- -14.29%
- 3개월 수익률
- -84.29%
- 6개월 수익률
- -91.80%
- 1년 수익률
- -98.76%
- 2년 수익률
- -
- 5일 평균거래량
- 5620
- 60일 평균거래량
- 18555
- 1년 평균거래량
- 17214
- 5d/60d 거래량 비율
- 0.30×
- 60d/1y 거래량 비율
- 1.08×
- 변동성(60일, 연환산)
- 631.79%
- BB 스퀴즈 스코어
- 1.97
- SMA50 비율
- 0.35
- SMA200 비율
- 0.09
- RSI (14)
- 43
- 20일 수렴도
- 0.34
- 52주 최고
- 3.09
- 52주 최저
- 0.02
- 고점 대비
- -99.03%
- 저점 대비
- 50.00%
펀더멘털 갱신: 2026-05-10T09:52:22+00:00 · 시세 갱신: 2026-05-10T06:48:51+00:00
회사 정보
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. On March 30, 2026, Lipella Pharmaceuticals Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Western District of Pennsylvania.